ArticleTheranostics2019
Radioembolization of Hepatocellular Carcinoma with Built-In Dosimetry: First
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 29 citations in OpenAlex.
- Ultra-Radiostable Covalent Conformationally Interlocked Networks Enabling a Universal Radiometal-Labeling Platform for Cancer Radioembolization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Disphosphate based hydrogel microspheres for targeted transarterial radioembolization and chemoembolization therapies.Journal of advanced research · 2026Article
- The evolution of surrogate microspheres in transarterial radioembolization: from SPECT prediction to multimodal AI-guided precision dosimetry.Theranostics · 2026Review
- A preclinical and first-in-human study of superstable homogeneous radiolipiodol for revolutionizing interventional diagnosis and treatment of hepatocellular carcinoma.Acta pharmaceutica Sinica. B · 2025Article
- Article
- Transarterial Radioembolization: Overview of Radioembolic Devices.Seminars in interventional radiology · 2023Review
- Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art.Journal of nanobiotechnology · 2023Review
- Microspheres as a Carrier System for Therapeutic Embolization Procedures: Achievements and Advances.Journal of clinical medicine · 2023Review
- Bench-to-bedside development of multifunctional flexible embolic agents.Theranostics · 2023Review
- Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma.Gels (Basel, Switzerland) · 2022Article
- CEP192 is a novel prognostic marker and correlates with the immune microenvironment in hepatocellular carcinoma.Frontiers in immunology · 2022Article
- Diagnostic Performance of Theranostic Radionuclides Used in Transarterial Radioembolization for Liver Cancer.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
A common form of treatment for patients with hepatocellular carcinoma (HCC) is transarterial radioembolization (TARE) with non-degradable glass or resin microspheres (MS) labeled with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.